The 5.33x price-to-book multiple is the only headline valuation metric that is positive, yet it is the least informative here because equity of roughly $689M rests on an $11.2B accumulated deficit rather than retained earnings — the multiple effectively prices the balance sheet, not the earnings stream. With forward P/E and EV/EBITDA unavailable and net margins of -18.0%, any implied multiple rests on hope of a turnaround rather than current earning power; the peer spread suggests the market is pricing Canopy's brand or optionality, not its operating performance, and that gap warrants close scrutiny if losses fail to narrow further.

Gross margin of 27.4% in 2027Q1 sits below the 34.8% recorded two years earlier and below peer benchmarks of 42.6% for Aurora and 41.4% for Cronos, suggesting the pricing environment has not turned structurally in Canopy's favor despite portfolio pruning. What matters more for true earning power is operating margin: at -27.2%, the company is still failing to cover its own overhead on revenue of $81.2M, and the swing from -146.6% to -27.2% reflects loss-magnitude improvement rather than demonstrated cost discipline, since SG&A continues to absorb nearly half the top line.

The improving ROIC trajectory is partly mechanical: with total assets contracting from $1.3B to $1.1B and PP&E declining slightly even as capex runs far below depreciation, the denominator is shrinking faster than losses, which flatters returns without any operational fix. ROE remains deeply negative at -2.1% to -40.9% across the series, and because book equity is externally funded rather than earned, any return-to-positive scenario would still require revenue growth that the asset base — asset turnover of just 0.07x — currently cannot support. Investors should treat the ROIC trend as debt-and-asset reduction rather than compounding return potential.

Asset turnover of 0.07x is anemic even for a cannabis cultivator, and the DSO-DPO gap shows Canopy pays suppliers far faster than it collects from customers, the opposite of the trade leverage seen in healthier consumer franchises — DPO of 49 days against DSO of 44 days provides no meaningful financing offset to the inventory drag. The cycle has narrowed from 214 days in 2025Q2, which may indicate slower write-downs or better demand-mix, but any inventory reduction below 150 days would be the clearest operational evidence that the business model can genuinely turn.

The liquidity picture is genuinely stronger than a year ago, when the current ratio was 1.39, and the debt-to-equity decline from 1.33 to 0.40 has reduced refinancing pressure — though the deleveraging appears to have come through balance-sheet restructuring rather than cash repayment. Critically, a large portion of current assets is inventory at 168 days, and if that stock is slow-moving, the effective cushion is smaller than the headline ratio implies. Liquidity should be judged against continuing cash burn, and even a sustained narrowing of outflows would leave the company dependent on the same external capital markets that built the equity base.